Home > Healthcare > Drug Device Combination > Hemostasis Products Market

Hemostasis Products Market Trends

Report ID: GMI5287
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Hemostasis Products Market Trends

Recent innovations, such as modified chitosan dressing, intranasal splint for nasal/sinus surgery and hemostatic foams have proved favorable for considerable industry gains. The demand for microfibrillar collagen hemostats has picked significant pace to demonstrate quick hemostasis and favorable outcomes in favor of the patient, as well as in some other documented issues. The growing emphasis on providing technologically superior hemostasis solutions will also drive the business expansion. For instance, in May 2023, Sysmex Corporation inked a global OEM agreement on hemostasis products with Siemens Healthcare Diagnostics Inc., for the supply of its OEM hemostasis diagnostic devices.

Authors: Mariam Faizullabhoy , Pratiksha Kamthe

Frequently Asked Questions (FAQ) :

Hemostasis products industry size was worth USD 1.6 billion in 2022 and is poised to record 5.8% CAGR from 2023-2032, driven by the escalating global prevalence of cardiac disorders.

Topical market accounted for USD 1.2 billion in 2022 and is estimated to record high demand through 2032 attributed to the advantages, such as ease of application, quick action, and reduced risk of complications.

North America market is expected to expand at 5.9% CAGR from 2023-2032 attributed to the presence of large geriatric population coupled with lifestyle-related factors such as obesity and sedentary habits

Some of the prominent hemostasis product companies are Johnson & Johnson, Pfizer, Baxter International, Medtronic, B. Braun Melsungen AG, Becton, Dickinson, and Company (BD), Tricol Biomedical, Hemostasis LLC, CuraMedical BV, and Teleflex Incorporated.